Absci and Caltech Join Forces, Bolstered by Major Grant, to Accelerate Affordable HIV Therapeutic Vaccine Development
10 Agosto 2023 - 7:00AM
Absci Corporation (Nasdaq: ABSI), a generative AI drug creation
company, today announced that leading researchers at the California
Institute of Technology (Caltech) in conjunction with Absci, a
leader in AI drug creation, received a grant from the Bill &
Melinda Gates Foundation. The grant supports the joint effort of
Caltech and Absci to discover affordable HIV therapeutic
vaccinations, with the goal of making a significant step forward in
the fight against the global HIV/AIDS epidemic.
The collaboration between Caltech and Absci, led by Dr. Pamela
Bjorkman, brings together cutting-edge research capabilities and
advanced technological expertise in structural biology and
immunology, protein design, synthetic biology, and generative AI.
By leveraging their combined strengths, the teams will work towards
the development of a novel HIV therapy that first exposes and then
binds to a highly conserved epitope binding site on HIV-1 to
potentially both treat and protect against infection from all
strains of HIV-1.
More than 40 years after the AIDS pandemic began, there is no
vaccine or cure for HIV. Antiretroviral therapies (ARTs) help many
people live longer, healthier lives, but they do not completely
eliminate the virus and must be taken for life. Additionally, the
cost and inaccessibility of these drugs disproportionately affect
millions of people from low-income and marginalized communities.
This new partnership between Caltech and Absci, facilitated by the
generous grant from the Gates Foundation, aims to address this
disparity by focusing on the affordability, scalability, and
accessibility of HIV therapeutic vaccinations. Combining the latest
advances and expertise across their respective fields, Caltech and
Absci aim to confront a challenge facing millions worldwide.
"We are thrilled to receive this grant from the Bill &
Melinda Gates Foundation," said Dr. Stephen Mayo, Bren Professor of
Biology and Chemistry and Merkin Institute Professor at Caltech and
project co-leader. "We’re committed to making transformative
contributions to society through research and innovation, and we
are excited to partner with Absci, who has developed a powerful de
novo AI antibody platform that is helping to unlock new therapeutic
possibilities. This collaboration with Absci allows us to combine
our expertise and work towards a common goal of developing
affordable HIV therapeutic vaccinations that can save lives and
bring hope to millions."
"We are honored to be partnering with Caltech on this critical
project," stated Sean McClain, Founder and CEO of Absci. "At Absci,
we are driven to transform lives through the power of generative AI
and synthetic biology. By joining forces with Dr. Pamela Bjorkman
and Dr. Stephen Mayo, and with support from the Gates Foundation,
we believe we can make significant strides towards developing
affordable HIV therapeutic vaccinations and positively impacting
global health."
About AbsciAbsci is a generative AI drug
creation company that combines AI with scalable wet lab
technologies to create better biologics for patients, faster. Our
Integrated Drug Creation™ platform unlocks the potential to
accelerate time to clinic and increase the probability of success
by simultaneously optimizing multiple drug characteristics
important to both development and therapeutic benefit. With the
data to learn, the AI to create, and the wet lab to validate, Absci
can screen billions of cells per week, allowing it to go from
AI-designed antibodies to wet lab-validated candidates in as little
as six weeks. Absci’s vision is to deliver breakthrough
therapeutics at the click of a button, for everyone. Absci's
headquarters is in Vancouver, WA, its AI Research Lab is in New
York City, and its Innovation Center is in Zug, Switzerland. Visit
www.absci.com and follow us on LinkedIn (@absci), Twitter
(@Abscibio), and YouTube.
Availability of Other Information about
AbsciInvestors and others should note that we routinely
communicate with investors and the public using our website
(www.absci.com) and our investor relations website
(investors.absci.com), including without limitation, through the
posting of investor presentations, SEC filings, press releases,
public conference calls and webcasts on these websites, as well as
on Twitter, LinkedIn, and YouTube. The information we post on these
websites and social media outlets could be deemed material. As a
result, investors, the media, and others interested in Absci are
encouraged to review this information regularly. The contents of
our website and social media postings, or any other website that
may be accessed from our website or social media postings, shall
not be deemed incorporated by reference in any filing under the
Securities Act of 1933, as amended.
Absci Forward-Looking StatementsCertain
statements in this press release that are not historical facts are
considered forward-looking within the meaning of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended, including statements
containing the words “will,” “may,” “pursues,” “anticipates,”
“plans,” “believes,” “aims,” “potential,” “forecast,” “estimates,”
“extends,” “expects,” and “intends,” or similar expressions. We
intend these forward-looking statements, including statements
regarding technology development efforts and the application of
those efforts, including acceleration of drug development
timelines, reducing the time and costs related to drug development,
improving clinical and patient outcomes, advancements toward in
silico drug design, drug discovery and development activities, and
the effective incorporation of our technology in drug design, and
research and technology development collaboration efforts, to be
covered by the safe harbor provisions for forward-looking
statements contained in Section 27A of the Securities Act and
Section 21E of the Securities Exchange Act. We make this statement
to comply with those safe harbor provisions. These forward-looking
statements reflect our current views about our plans, intentions,
expectations, strategies, and prospects, which are based on the
information currently available to us and on assumptions we have
made. We can give no assurance that the plans, intentions,
expectations, or strategies will be attained or achieved.
Furthermore, actual results may differ materially from those
described in the forward-looking statements and will be affected by
a variety of risks and factors that are beyond our control,
including, without limitation, risks and uncertainties relating to
our ability to effectively collaborate on research, drug discovery
and development activities with our partners or potential partners;
along with those risks set forth in our most recent periodic report
filed with the U.S. Securities and Exchange Commission, as well as
discussions of potential risks, uncertainties, and other important
factors in our subsequent filings with the U.S. Securities and
Exchange Commission. Except as required by law, we assume no
obligation to update publicly any forward-looking statements,
whether as a result of new information, future events, or
otherwise.
Absci Media Contactpress@absci.comAbsci
Investor Contactinvestors@absci.com
AbSci (NASDAQ:ABSI)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
AbSci (NASDAQ:ABSI)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024